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Summary The NAD(P)H quinone oxidoreductase (NQ01 EC 1.6.99.2) is an important biotransformation enzyme system that is also known
to metabolize important novel chemotherapeutic compounds. The gene that codes forthis enzyme has recently been found to be polymorphic
in humans. Here, we describe the ethnic distribution of the polymorphism and note that this may have implications for anti-tumour drug
development and use.
Keywords: polymorphism; NQ01; DT Diaphorase; ethnicity; second cancer
The ability of NAD(P)H quinone oxidoreductase (NQO1: EC
1.6.99.2) tobioactivate anti-tumourquinones as well as theelevated
NQO1 activity in certain tumours has led to aconsiderable focus on
NQO1 in enzyme-directed drug development (Riley andWorkman,
1992; Workman, 1994; Ross et ala, 1993, 1994; 1996a). NQOl has
been shown to bioactivate both mitomycin C (Siegel et al, 1990)
and E09 (Walton et al, 1991). Correlations between NQO1 activity
and either mitomycin C or E09 sensitivity have been described in
cellular systems (Riley and Workman, 1992; Workman, 1994; Ross
et al, 1996) but, more recently, significant correlations between
NQOl activity and mitomycin C and E09 sensitivity have been
demonstrated in 69 cell lines in the NCI human tumour cell line
panel (Fitzsimmons et al, 1996). The cytotoxicity of streptonigrin
has also been reported to exhibit an excellent correlation with
NQO1 activity in cell lines ofthe NCI panel (Paul et al, 1994). One
significantimplication ofthis work is thatknowledge ofaparticular
tumour's level of activating or deactivating enzymes may help in
the selection of patients to receive specific anti-cancer therapies,
and thereby achieve improved therapeutic selectivity. An important
consideration in the development of these approaches is the
possible effects of inherited variation in the genes encoding
bioreductive enzymes. A further aspect in assessing the general
applicability of these strategies is the genetic differences related
to the racial and ethnic constitution ofpatient populations.
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Recently, a C to T transition at basepair 609 of exon 6 in the
gene encoding NQO1 has been described (Traver et al, 1992;
Rosvold et al, 1995; Ross et alb, 1996). The variant allele is
thought to code for a proline to serine amino acid substitution in
codon 187 and is associated with a loss of NQO1 protein and
enzyme activity (Traver et al, 1992; Rosvold et al, 1995; Ross et
alb, 1996). The polymorphic NQO1 enzyme is a dimeric FAD-
containing cytosolic protein that catalyses the two-electron reduc-
tion of a variety of quinone compounds (Riley and Workman,
1992; Workman, 1994; Ross et al, 1993, 1994). NQO1 functions
as a mechanism for the reductive activation of a growing number
ofchemotherapeutic agents (Table 1).
METHODS
Because of the increasingly prominent role of bioreductive drugs
in cancer chemotherapy and the potential for genetic hetero-
geneity, we examined the ethnic variation in the prevalence of
the NQOI polymorphism in 529 healthy subjects including
Caucasians, Hispanics, African-Americans and Asians.
We used apolymerase chain reaction (PCR)-based approach for
genotyping; briefly, a 211-bp PCR fragment was amplified from
DNA isolated from whole blood using the sense primer (5'-
TCCTCAGAGTGGCATTCTGC-3') and antisense primer (5'-
TCTCCTCATCCTGTACCTCT-3'). The variant allele is detected
using a Hinfl restriction digest run on 1.8% agarose gels. The
African-American, Mexican-American and Caucasian individ-
uals were healthy adult control subjects participating in lung
cancer case-control studies. The Asian participants were healthy
workers in Korea or participants in a longitudinal study of repro-
duction in mainland China.
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Table 1 Chemotherapeutic agents metabolized by NQO1
Mitomycin C Diaziquone
Tirapazaminea Streptonigrin
E09 PDZQ
Porofiromycin MeDZQ
Mitoxantrone CB1954
Ametantrone
PDZQ, 2,5-diaziridinyl-3-phenyl-1,4-benzoquinone; MeDZQ, 2,5-diaziridinyl-
3,6-dimethyl-1,4-benzoquinone; E09,3-hydroxymethyl-5-aziridinyl-1-methyl-
2-(1 H-indole-4,7 dione)-propenol; CB1954, 5-(aziridin-1-yl)-2,4-
dinitrobenzamide. aAIl compounds are bioactivated by NOO1 except
tirapazamine, which is detoxified by NQO1.
Table 2 NQO1 genotype frequencies in different ethnic groups
Wt*/Wt WW** VN Allele
(%) (%) (%) frequency
Ethnic group (Wt) (V)
Non-Hispanic White 64 (56.1) 45 (39.5) 5 (4.4)a (0.75) (0.25)
(n= 114)
Mexican Hispanic 52 (32.3) 84 (52.2) 25 (15.5)b (0.57) (0.43)
(n = 161)
African-American 83 (61.0) 46 (33.8) 7 (5.2k (0.78) (0.22)
(n= 136)
Asian 37 (31.4) 57 (48.3) 24 (20.3)d (0.56) (0.44)
(n= 118)
Korean (n = 69) 23 (33.3) 33 (47.8) 13 (18.8) (0.58) (0.42)
Chinese (n = 49) 14 (28.6) 24 (50.0) 11 (22.4) (0.53) (0.47)
Numbers in parentheses do not always add up to 100 because of
rounding. *Wt, wild-type allele; **V, variant allele. aSignificantly different from
b(p < 0.05) and d(p< 0.05). cSignificantly differentfrom b(p< 0.05) and
d(p< 0.05).
RESULTS
The prevalence of the NQOl polymorphism in different ethnic
groups is shown in Table 2. We found that approximately 5% of
African-Americans were homozygous for the variant NQO1
allele. Interestingly, 5% ofthe Caucasians were similarly homozy-
gous for this trait. The Asian population had the highest frequency
of homozygous variant individuals with 20.3% overall (18.8% in
Koreans and 22.4% in Chinese). The Mexican-American volun-
teers were only slightly lower in homozygous variant prevalence
compared with Asians, with 15.5% having two copies of this
allele. The prevalence of heterozygous individuals ranged from
34% to 52%. All ofthe allele frequencies were in Hardy-Weinberg
equilibrium.
DISCUSSION
These results demonstrate that the variant allele ofthe NQO1 gene
is remarkably common in all ethnic groups examined to date. It
has been shown that homozygous variant cells have a complete
absence ofNQOl protein and activity (Traver et al, 1992; Rosvold
et al, 1995; Ross et al, 1996). Therefore, our results would predict
that 5-20% of patients (depending upon ethnicity) will have
diminished metabolic activation ofbioreductive compounds. This
could adversely affect the outcome of such therapies because the
tumour-specific action of these agents is thought to depend on
increased expression of NQOl in tumours compared with normal
tissue. Unlike carriers of two of the variant alleles, heterozygotes
may have intermediate sensitivity ofnormal tissue while retaining
enhanced enzyme expression in tumours. The precise effect of
different NQOl genotypes is unknown. Consequently, it is crucial
that well-controlled studies be carried out to define the phenotypic
effects ofheterozygote and homozygote NQO1 expression, as this
understanding may afford novel opportunities to increase the
efficacy ofbioreductive chemotherapeutics.
Because NQOl can potentially affect the generation oftoxic as
well as therapeutic intermediates, genetic variations that affect
NQOl activity may impact upon both the acute and chronic side-
effects of cancer treatments. Increased myelosuppression associ-
ated with exposure to the known leukaemogen, benzene, occurs in
persons carrying the variant NQOl gene (Rothman et al, 1996).
Hence, the dose-limiting toxicity of bioreductive drugs could
also be affected by the NQO1 polymorphism, and could vary
with its ethnic distribution. Long-term complications of cancer
chemotherapy include the induction of second tumours (Platz
et al, 1996). For example, combination therapy for breast cancer
including mitomycin C and mitoxantrone is known to carry a risk
for secondary leukaemia (Philpott et al, 1993). Investigation ofthe
association ofNQO1 genotypes with adverse outcome could assist
in ongoing efforts to select those patients most likely to benefit
from a particular drug orcombination ofdrugs.
Although our data show that the NQOI polymorphism is
common, they also indicate significant ethnic differences in allele
frequencies; homozygous variants were fourfold more common
among Asians compared with Caucasians. Importantly, it is also
well known that, for some cancers, the success of treatment is
influenced by race and ethnicity (Elledge et al, 1994; Modiano
et al, 1995). For example, Berenberg (1991) has suggested that
differences in drug distribution, elimination and metabolism
related to genetics could explain the variability in outcome of
treatment for breast carcinoma identified between Asian and
Caucasian women. Our results emphasize the importance of
considering the genetic heterogeneity of diverse patient popula-
tions in developing and evaluating bioreductive agents used in
cancer chemotherapy.
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